Meeting
2024 ASCO Annual Meeting
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).
Authors
Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Solange Peters , Stephane Champiat , Tatsuya Yoshida , Nicolas Dorleacq , Yiyuan Ma , Lijiang Geng , Ticiana Leal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT06077500
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS8127)
DOI
10.1200/JCO.2024.42.16_suppl.TPS8127
Abstract #
TPS8127
Poster Bd #
383a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.
First Author: Heya Batah
Poster
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
First Author: Aditya Juloori
Poster
2023 ASCO Annual Meeting
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
First Author: Lionel Falchero